CA-LAMBDATEST
24.1.2024 18:01:34 CET | Business Wire | Press release
LambdaTest, a leading cloud-based unified testing platform announced the launch of its SmartUI SDK. This tool simplifies visual regression testing for its users in just one click and finds Visual UI Regression bugs easily with the help of Smart Testing.
SmartUI SDK seamlessly integrates into existing testing suites, transforming the approach to visual regression testing. This robust solution empowers users to effortlessly capture, compare, and analyze screenshots across various browsers and resolutions, ensuring comprehensive coverage and accuracy in visual testing endeavors.
The SmartUI dashboard serves as a powerful tool for identifying mismatches from the existing baseline screenshots.
The SmartUI SDK by LambdaTest brings substantial benefits to the testing process, with three key areas of impact:
-
Reduced Test Execution Time:
SmartUI SDK significantly reduces test execution time, enhancing efficiency and accelerating the release cycles. -
Optimized Testing Resources:
Users experience better utilization of testing resources, ensuring a streamlined and resource-efficient testing environment. -
Easy Configurations:
Maintenance of different configurations will be reduced and easily configured with basic changes rather than changing the complete wiring of test suites.
Mayank Bhola, Head of Product and Co-Founder, LambdaTest said, “We are pleased to announce the launch of SmartUI SDK, which addresses the crucial challenges faced by our users in visual regression testing. By reducing test execution time and optimizing testing resources, SmartUI SDK aligns with our commitment to providing innovative solutions that empower our users to achieve seamless and efficient testing processes.”
For more details on SmartUI SDK: https://www.lambdatest.com/support/docs/smartui-selenium-js-sdk/
About LambdaTest
LambdaTest is an intelligent and omnichannel enterprise execution environment that helps businesses drastically reduce time to market through Just in Time Test Orchestration (JITTO), ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
- Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.
- HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to reduce quality test time, helping developers build software faster.
For more information, please visit, https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124383390/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom